SerenaGroup Launches Groundbreaking Diabetic Foot Ulcer Study with a Focus on Real-World Impact

By Daniel Casciato

For people living with diabetes, a seemingly minor foot injury can evolve into a serious, life-altering condition. Diabetic foot ulcers (DFUs) are among the most complex and dangerous complications of diabetes, often leading to infection, hospitalization, and even amputation. Now, SerenaGroup, a nationally recognized leader in wound care, is conducting a new research study aimed at changing that narrative for patients in Western Pennsylvania and beyond.

“Diabetic foot ulcers are something I’m deeply passionate about addressing, because they’re not just a medical issue; they affect every aspect of a person’s life,” says Laura Serena, chief research officer at SerenaGroup. “For people living with diabetes, these wounds can be stubborn and slow to heal, often because of poor circulation and nerve damage. That means small problems can quickly become serious, leading to infections or even amputations.”

The new study, currently underway at SerenaGroup clinics, takes a patient-first approach that goes beyond traditional clinical trials. Serena emphasized that while many research efforts are focused on numbers and lab data, SerenaGroup’s mission is to center the human experience.

“What really sets this study apart is our patient-first approach and our drive to bring the latest science directly into the clinic,” Serena explains. “We’re not just looking at numbers—we’re looking at real people, in real-world situations, and asking how we can make a meaningful difference.”

In addition to evaluating how well the treatment promotes wound healing, the study is designed to capture other key outcomes like infection rates, comfort, and long-term limb health. “Our hope is to generate insights that will truly move the needle for people with diabetic foot ulcers,” she says.

Why Four Weeks Matters

One important requirement for participation in the study is that a patient’s ulcer must have been present for at least four weeks. This might seem like a small detail, but it’s a crucial part of the study design.

“We set the four-week minimum because we want to focus on wounds that are genuinely hard to heal—those that haven’t responded to standard care,” Serena notes. “If a wound is still open after four weeks, research has proven the wound is much less likely to heal on its own, and that’s where new treatments can really make a difference.”

A Seamless and Supportive Patient Experience

The patient journey through the study is built to be as smooth, informative, and supportive as possible. From the first visit through every follow-up, SerenaGroup ensures participants are well cared for.

“From the very first visit, our goal is to make patients feel supported and informed,” according to Serena. “We start with a thorough evaluation and walk each person through what to expect. Throughout the study, patients receive regular check-ins, advanced dressings, and any new treatments we’re testing, all overseen by our dedicated wound care team.”

This compassionate, hands-on approach is more than just a study protocol—it’s a core part of the organization’s identity. “We keep a close eye on progress, address any concerns right away, and make sure every patient feels cared for every step of the way. That’s the SerenaGroup promise,” she adds.

Breaking Down Barriers to Access

One of the most powerful aspects of the study is its accessibility. SerenaGroup offers study-related treatments at no cost, with no insurance required, removing a significant barrier for many patients.

“I know that cost and insurance hurdles keep far too many people from getting the care they need,” Serena says. “By offering study-related treatment at no cost and not requiring insurance, we’re opening the door to everyone who qualifies. It’s incredibly important to me—and to all of us at SerenaGroup—that innovative wound care isn’t just for those with the right coverage or resources.”

Looking Beyond the Wound

While wound closure remains an essential benchmark, SerenaGroup’s research team is looking deeper into outcomes that matter most to patients’ everyday lives.

“Wound closure is important, but it’s not the whole story,” says Serena. “We’re also looking closely at things like infection prevention, reducing the risk of amputation, pain levels, mobility, and overall quality of life. These are the outcomes that matter most to our patients, and they’re at the heart of what we’re trying to achieve with this research.”

A Vision for the Future of Wound Care

Looking ahead, Serena believes the study could have long-term implications for how wound care is delivered, not just in Western Pennsylvania, but nationwide.

“I truly believe this research can be a turning point, not just for SerenaGroup, but for wound care everywhere,” she says. “By sharing what we learn and advocating for evidence-based practices, we hope to raise the bar for care in Western Pennsylvania and beyond. My vision is a future where chronic wounds don’t hold people back, and where everyone has access to the best possible treatments, no matter where they live or what their circumstances are.”

For more information about the study or to find out if you qualify, visit https://form.jotform.com/250075562354152 or contact your local clinic.